Table 5.
Commonly prescribed FDCs
| Composition | Frequency (proportion) | M.C. strength of combination (frequency) |
|---|---|---|
| Diabetes FDCs | N = 222, | |
| (18.86% of formulations) | ||
| Metformin + glimepiride | 142 (64%) | 1000+2 mg (74) |
| 1000+1 mg (50) | ||
| Metformin + vildagliptin | 28 (12.6%) | 1000+50 mg (24) |
| Metformin + teneligliptin | 13 (6.4%) | 1000+20 mg (11) |
| Metformin + sitagliptin | 8 (3.6%) | 1000+50 mg (8) |
| Premixed insulin | ||
| (NPH + regular) | 20 (9%) | 70:30 (18) |
| Metformin + glimepiride + Pioglitazone | 5 (2.25%) | 1000+1 + 15 mg (3) |
| Nondiabetes FDCs | N = 267 | |
| (22.68% of formulations) | ||
| Aspirin + atorvastatin | 74 (27.7%) | 75+20 mg (55) |
| 75+10 mg (19) | ||
| Telmisartan + amlodipine | 47 (17.6%) | 40+5 mg |
| Aspirin + clopidogrel | 8 (3%) | 150+75 mg |
| Telmisartan + amlodipine + hydrochlorthiazide | 5 (1.9%) | 40+5 + 12.5 mg |